Course Description
Treatment guidelines for all major psychiatric illnesses recommend routine monitoring for patients receiving medications to treat those illnesses. Guidelines recommend therapeutic drug monitoring when appropriate. Adverse effect monitoring is also recommended, with a focus on movement disorders and metabolic adverse effects with antipsychotics. Despite these published recommendations, not all patients receiving psychotropic medication have this monitoring performed as recommended due to time constraints and lack of provider knowledge. As more patients with mental illness are treated within primary care settings, it is important that primary care and mental health providers work together to appropriately monitor psychotropic medications and their adverse effects. This presentation will explore how psychiatric pharmacists are in a key position to perform this monitoring, educate their colleagues, and help improve overall health outcomes for patients.
Learning Objectives
- Develop a monitoring plan for a patient receiving a psychotropic medication.
- Recommend adjustments to psychotropic monitoring plans in special patient populations.
- Implement strategies to increase appropriate monitoring of psychiatric medications in primary care settings.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
BCPPs desiring an evidence-based focus on an emerging area of practice and contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who learn best from didactic presentations, are auditory and visual learners, and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Faculty
View biographical information
Bridget Bradley, PharmD, BCPP
Clinical Pharmacist
OHSU Primary Care at Beaverton
Hillsboro, OR
Bridget Bradley graduated with a doctor of pharmacy degree from Oregon State University College of Pharmacy and completed residency at the Roseburg VA Healthcare System and then Avera Behavioral Health Center in Sioux Falls, South Dakota. She is current an ambulatory care clinical pharmacist within primary care at Oregon Health & Science University. This position allows Bridget to practice at the top of her license along with working within a health-system that is billing for clinical pharmacy services. She currently practices with collaborative practice agreements for treatment of diabetes and hypertension. She also services as resource for psychiatric medication within her clinics.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 10/13/2023
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-23-014-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.